Risk Markers in the Acute Coronary Syndromes (RACS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00521976|
Recruitment Status : Completed
First Posted : August 28, 2007
Results First Posted : August 11, 2009
Last Update Posted : June 15, 2015
The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples collected at admission.
The second purpose of this study is to assess the incremental prognostic value of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP).
A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane.
|Condition or disease|
|Chest Pain Coronary Artery Disease Unstable Angina Pectoris Myocardial Infarction|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||871 participants|
|Official Title:||An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.|
|Study Start Date :||November 2002|
|Actual Primary Completion Date :||December 2005|
|Actual Study Completion Date :||December 2005|
Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
- Total Mortality. [ Time Frame: 24 months. ]
- Recurrent Troponin-T (TnT) Positive Events [ Time Frame: 24 months. ]Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT >0.05 ng/mL with a pattern of gradual rise and fall in TnT
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00521976
|Stavanger University Hospital|
|Stavanger, Rogaland, Norway, 4068|
|Principal Investigator:||Dennis WT Nilsen, MD PhD FESC||Stavanger University Hospital, Dept. of Cardiology|